Journal
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
Volume 15, Issue -, Pages 1265-1269Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/CCID.S373937
Keywords
primary cutaneous diffuse large B-cell lymphoma; leg type; rituximab plus cyclophosphamide; doxorubicin; vincristine; prednisone (R-CHOP); remission
Categories
Ask authors/readers for more resources
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LTs) is a rare and aggressive form of cutaneous B-cell lymphoma with poor prognosis and low therapeutic response. This study presents a case of a patient with indolent PCDLBCL-LT who achieved nearly 100% clearance after receiving chemotherapy.
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LTs) is a rare and the most aggressive type of the cutaneous B-cell lymphoma with poor prognosis and low therapeutic response. It mostly affects elderly women, with a 5-year survival rate of 50% if not efficiently treated. We present a 28-year-old male patient with indolent PCDLBCL-LT who reached nearly 100% clearance after six rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy sessions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available